Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ViiV Healthcare
With
GlaxoSmithKline
Age
18–70
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Males and females, ages 18 to 70 years, inclusive
BMI: 18.5 to 38 kg/m2
Body weight great or equal to 45.5 kg
Subjects with hepatic impairment
Subjects with hepatic impairment must be on a stable dose of medication and/or treatment regimen
Healthy subjects to the extent possible matched to the first four subjects with hepatic impairment with regard to age, body weight, and sex, as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
You may not be if
Any major surgery within 4 weeks of study drug administration
Donation of blood to a blood bank or in a clinical study (except a screening visit) within 4 weeks of study drug administration (within 2 weeks for plasma only)
Subject has required additional medication for hepatic encephalopathy within 12 months (6 months for severe hepatic impairment) prior to dosing
Presence of severe ascites or edema in subjects, as judged by the PI
Clareo Health | Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects
